1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.
Assess the elimination of PD-0332334 from the blood with hemodialysis
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
8
A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
Pfizer Investigational Site
Orlando, Florida, United States
Maximum plasma concentration (Cmax) of PD-0332334 and time of maximum plasma concentration (Tmax). Half-life of PD-0332334 in this patient population with hemodialysis and without hemodialysis
Time frame: 0 to 8 days
Hemodialysis clearance of PD-0332334 from the blood, the total amount and fraction of total dose of PD-0332334 removed from the blood via hemodialysis, and the half-life of drug removal from the blood via hemodialysis
Time frame: 0 to 8 days
Area under the curve (AUC) of PD-0332334 from time of study medication administration to infinity (AUCinf); AUC of PD-0332334 from time of study medication administration to last quantifiable plasma concentration (AUClast).
Time frame: 0 to 8 days
Assess adverse events, findings from physical examinations, clinical safety laboratory assessments, ECG, vital signs.
Time frame: 0 to 8 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.